Topical calcipotriol in childhood psoriasis - 11/09/11
From the Department of Dermato-Venereology (Pediatric Dermatology Unit), University Hospital Rotterdama; Hospital Ste-Justine and University of Montrealb; Department of Dermatology, Centralhospital, Kristianstadc; British Columbia's Children's Hospital and University of British Columbia, Vancouverd; in private practice, Torontoe and Winnipegf; the Division of Dermatology, McMaster University Faculty Health Science, Hamiltong; the Department of Dermatology, Orebro Medical Center Hospitalh; and Leo Pharmaceutical Products, Ballerup.i
Abstract |
Background: The use of topical calcipotriol in adults with psoriasis is safe and effective.
Objective: Our purpose was to study the efficacy and safety of calcipotriol in children.
Methods: A multicenter, prospective, 8-week, double-blind, parallel group study was conducted in 77 children. Response to treatment was assessed by means of the Psoriasis Area and Severity Index (PASI) in that the intensity of redness, thickness, and scaliness as well as the area involved are scored. The children were 2 to 14 years of age and had stable psoriasis, involving less than 30% of the body surface. Forty-three children were assigned to receive calcipotriol ointment and 34 to receive placebo. Nine children dropped out of the study, six in the calcipotriol-treated group and three in the placebo-treated group.
Results: Both treatment groups (calcipotriol and placebo) showed significant improvement in PASI from baseline to the end of treatment, and the difference was not statistically significant. No serious side effects, in particular including those relating to calcium and bone metabolism, were recorded.
Conclusion: Calcipotriol ointment was statistically significantly more effective than its vehicle in terms of the investigator's overall assessment and reduction in redness and scaliness but not in terms of PASI score.
(J Am Acad Dermatol 1997;36:203-8.)
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by LEO Pharmaceutical Products, Ballerup, Denmark. |
| Reprint requests: Arnold P. Oranje, MD, PhD, Pediatric Dermatology Unit, University Hospital Rotterdam/Sophia-Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. |
 | 0190-9622/97/$5.00 + 0 16/1/77695 |
Vol 36 - N° 2
P. 203-208 - février 1997 Retour au numéro
Article précédent
- Epiluminescence microscopy of small pigmented skin lesions: Short-term formal training improves the diagnostic performance of dermatologists
- Michael Binder, Margot Puespoeck-Schwarz, Andreas Steiner, Harald Kittler, Marcus Muellner, Klaus Wolff, Hubert Pehamberger, From the Departments of Dermatologya and Emergency Medicine,b University of Vienna Medical School, and the Department of Dermatology, Wilhelminenspital.c
- Circulating adhesion molecules as prognostic factors for cutaneous melanoma
- Helmut Schaider, Irene Rech-Weichselbraun, Erika Richtig, Hannes Seidl, H.Peter Soyer, Josef Smolle, Helmut Kerl, From the Department of Dermatology, University of Graz,a and Bender Med Systems, Vienna.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?